Read our latest blog: LinkLight™ Protein-Protein Interaction AssaysLearn More

Hundreds of oncology therapies approved by the FDA and global regulatory agencies were supported by our science. We deliver the quality, speed, and scientific rigor that 2,000+ clients worldwide count on to advance their most promising drug candidates.

DISCOVERY SERVICES
PRECLINICAL SERVICES
CLINICAL SUPPORT SERVICES

Your Drug Discovery and Development Partner Since 2001

For over 25 years, leading pharmaceutical, biotech, and academic organizations have trusted Reaction Biology to advance their most critical drug candidates.

Our scientists act as consultative partners who interpret results, recommend next steps, and orient their work around your milestones. Across our facilities in the US and Europe, gold-standard techniques are powered by industry-leading instrumentation, providing the flexibility to design bespoke studies while delivering quality data held to the highest standards of scientific rigor.

Quality systems are built for the audits your program will eventually require. Reaction Biology Europe operates under an ISO 9001:2015-certified quality management system for the development, production, and sale of recombinant protein products, biochemical, cellular, and immuno-oncology assay services, and in vivo testing services. BSL2-equipped labs enable in vivo efficacy studies across a broad range of therapeutic modalities: from small molecules, antibodies, and ADCs to oncolytic viruses and bacteria-based agents.

Company Facts

  • Founded in 2001 in Malvern, Pennsylvania, Reaction Biology was created to provide outstanding kinase-based drug discovery to labs worldwide.
  • We have quickly become the go-to CRO for kinase screening and holding true to our promise for high-quality data and support we have continuously developed assays for new target classes. 20 years later, we offer thousands of assays and a platform for integrated drug discovery.
  • Our global footprint has grown to include three other research locations in Hershey, Pennsylvania (formerly vivoPharm, LLC), Freiburg, Germany (formerly ProQinase GmbH), and Heidelberg, Germany (Bioassay GmbH).

Malvern (Global HQ)

Malvern (Global HQ)
PA, USA

Hershey

Hershey
PA, USA

Freiburg

Freiburg
Freiburg, Germany

Heidelberg

Heidelberg
Heidelberg, Germany

Preclinical Drug Discovery Platform

Reaction Biology’s team of PhD scientists will take your drug discovery project from target validation through hit identification and hit to lead phases and provide lead optimization studies either on a fee-for-service basis or as integrated partner.

 

The CBC Network

We are proud to be part of the Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program, which brings together chemical biologists and molecular oncologists from government, industry, and academia to create new cancer medicines in epigenetic, kinase, and other areas.

As a Specialized Center, we provide uniquely focused technologies that facilitate the successful progression of NExT discovery projects at specific discovery stages.

  • Beryllium Discovery Corp. (UCB)
  • University of California, San Francisco
  • Evotec Compound Management
  • SRI International
  • Sanford Burnham Prebys Medical Discovery Institute
  • The Scripps Research Institute
  • Vala Science Inc.
  • SAMDI Tech
  • Torrey Pines Institute for Molecular Studies
  • University of New Mexico
  • Arizona State University
  • Purdue University
  • University of Pittsburgh
  • Southern Research Institute
  • Albany Molecular Research Inc.
  • Xtal Bio Structures Inc.
  • Pharmaron
  • Reaction Biology Corp.
  • NCATS Chemical Genomics Center
  • University of North Carolina at Chapel Hill
  • Vanderbilt University
  • Emory University
  • University of Chicago